Highest-materiality recent filing
Elected Aaron G.L. Fletcher, Ph.D. and Jason Keyes as Class II directors for three-year terms through 2029.
Actuate Therapeutics receives FDA IND clearance for oral elraglusib Phase 1/2 study
FDA cleared IND for Phase 1/2 study of oral elraglusib tablet in advanced solid tumors; initiation planned for 2H 2026.
Actuate Therapeutics appoints former Mersana CEO Martin Huber to board
Board expanded from 7 to 8; Huber appointed as Class III director effective May 1, 2026.
Actuate Phase 2 pancreatic cancer trial meets OS endpoint; elraglusib+GnP reduces death risk 38%
Median OS 10.1 mo (elraglusib/GnP) vs 7.2 mo (GnP alone); HR=0.62, p=0.02.
Actuate Therapeutics enters $100M ATM equity offering agreement with B. Riley and Craig-Hallum
Agreement allows sale of up to $100M of common stock through agents B. Riley Securities and Craig-Hallum Capital Group.
Actuate Therapeutics lists official disclosure channels including social media
Company announced it will use website, press releases, SEC filings, and social media for material information.
Actuate Therapeutics prices $15M public offering of 2.14M shares at $7.00/share
Offers 2,142,858 shares at $7.00/share; gross proceeds ~$15M before discounts and expenses.
Actuate Therapeutics raises ~$4.7M in private placement of common stock and warrants
Gross proceeds of approx. $4.7M from sale of 666,497 shares at $7.00/share and warrants to purchase 666,497 shares.
Phase 2 (Actuate-1801 Part 3B) data of elraglusib with gemcitabine/nab-paclitaxel showed overall survival benefit in first-line metastatic pancreatic cancer.
Actuate reports Phase 2 elraglusib/GnP meets primary OS endpoint in mPDAC
mOS 10.1 months vs 7.2 months for GnP alone, HR=0.63, log-rank p=0.01, 37% risk reduction.
Actuate Therapeutics shareholders elect three Class I directors, ratify Crowe as auditor
Dr. Roger Sawhney re-elected with 14,216,991 votes for, 1,200 withheld.
Elraglusib plus GnP showed statistically significant overall survival improvement vs GnP alone in first-line mPDAC.
Actuate Therapeutics enters $50M equity line with B. Riley, can sell shares at 3% VWAP discount
Company may sell up to $50M of common stock to B. Riley Principal Capital II over 36 months at a 3% discount to VWAP.
Actuate Therapeutics sets first annual meeting for May 22, 2025; deadlines announced
First Annual Meeting of Stockholders will be held virtually on May 22, 2025.
1-year survival rate 43.6% in elraglusib+GnP arm vs 22.5% in GnP alone (p=0.002); median OS 9.3 vs 7.2 months (HR=0.63, p=0.016).
Actuate Therapeutics receives FDA Rare Pediatric Disease Designation for elraglusib in Ewing sarcoma
FDA grants Rare Pediatric Disease Designation for elraglusib, a GSK-3β inhibitor, to treat Ewing sarcoma.
KMJ Corbin & Company LLP resigned as auditor on Aug 19, 2024; Crowe LLP appointed same day.
Actuate Therapeutics completes IPO of 2.8M shares at $8.00, net proceeds $19.2M
IPO closed Aug 14, 2024: 2,800,000 shares at $8.00/share, net proceeds $19.2M.
On May 1, 2026, the Board of Directors ("Board") of Actuate Therapeutics, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Martin H. Huber, MD, to the Board.
each of Jason Keyes, Roger Sawhney, and Amy Ronneberg were appointed to the Company’s Board of Directors (the “Board”) on May 20, 2024.
each of Jason Keyes, Roger Sawhney, and Amy Ronneberg were appointed to the Company’s Board of Directors (the “Board”) on May 20, 2024.
each of Jason Keyes, Roger Sawhney, and Amy Ronneberg were appointed to the Company’s Board of Directors (the “Board”) on May 20, 2024.
Les Kreis, Jr. resigned from the Board effective immediately prior to the closing of the Company’s initial public offering.
Max materiality 0.90 · Median 0.70 · Most common event other_material